Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF

About this episode

Drs. Maria Pabon and Robert Mentz discuss the role of mineralocorticoid receptor antagonism in heart failure, focusing on nonsteroidal MRAs and risk-based treatment strategies.

CME credits: 0.25 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/ In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, cardiac-renal distribution, and downstream anti-fibrotic and anti-inflammatory signaling. Faculty address the principle that symptom stability does not equate to disease stability, offering strategies to identify patients with HFpEF or HFmrEF who may benefit from a risk-based treatment approach. =

People in this episode

Guests: Maria Pabon, Robert Mentz

Topics covered

• mineralocorticoid receptor antagonism
• heart failure
• risk-based treatment
• HFpEF
• HFmrEF
• anti-fibrotic signaling
• anti-inflammatory signaling

Keywords

• mineralocorticoid receptor antagonism
• heart failure
• HFpEF
• HFmrEF
• nonsteroidal MRAs
• anti-fibrotic
• anti-inflammatory

Mentioned in this episode

Organizations: ReachMD

More episodes of ReachMD CME

• Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities · April 24, 2026 · 14 min
• Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management · April 20, 2026 · 1h 2m
• Retina Rumble: Debating Modern Treatment Options · April 15, 2026 · 33 min
• Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies · April 10, 2026 · 58 min
• Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source · April 7, 2026 · 14 min
• Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors · March 31, 2026 · 14 min